{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T19:48:50Z","timestamp":1768074530753,"version":"3.49.0"},"reference-count":26,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2017,5,25]],"date-time":"2017-05-25T00:00:00Z","timestamp":1495670400000},"content-version":"vor","delay-in-days":24,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Rheum Dis"],"published-print":{"date-parts":[[2017,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aim<\/jats:title><jats:p>To evaluate efficacy and safety of secukinumab in Asian patients with active ankylosing spondylitis (<jats:styled-content style=\"fixed-case\">AS<\/jats:styled-content>) via a pooled subgroup analysis from two phase 3 studies, <jats:styled-content style=\"fixed-case\">MEASURE<\/jats:styled-content> 1 (<jats:styled-content style=\"fixed-case\">NCT<\/jats:styled-content>01358175) and <jats:styled-content style=\"fixed-case\">MEASURE<\/jats:styled-content> 2 (<jats:styled-content style=\"fixed-case\">NCT<\/jats:styled-content>01649375).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In <jats:styled-content style=\"fixed-case\">MEASURE<\/jats:styled-content> 1, patients were randomized to intravenous secukinumab 10 mg\/kg or placebo at baseline, Weeks 2 and 4, followed by subcutaneous (s.c.) secukinumab 150 mg, 75 mg or placebo every 4 weeks (q4w) at Week 8. In <jats:styled-content style=\"fixed-case\">MEASURE<\/jats:styled-content> 2, patients were randomized to s.c. secukinumab 150 mg, 75 mg or placebo at baseline, Weeks 1, 2 and 3, and q4w starting at Week 4. Efficacy outcomes were SpondyloArthritis International Society (<jats:styled-content style=\"fixed-case\">ASAS<\/jats:styled-content>) 20\/40, high\u2010sensitivity C\u2010reactive protein (hs<jats:styled-content style=\"fixed-case\">CRP<\/jats:styled-content>), <jats:styled-content style=\"fixed-case\">ASAS<\/jats:styled-content>5\/6, Bath Ankylosing Spondylitis Disease Activity Index, Short Form\u201036 physical component summary, <jats:styled-content style=\"fixed-case\">AS<\/jats:styled-content> quality of life (QoL), <jats:styled-content style=\"fixed-case\">ASAS<\/jats:styled-content> partial remission, and Ankylosing Spondylitis Disease Activity Score \u2013 <jats:styled-content style=\"fixed-case\">CRP<\/jats:styled-content> at Weeks 16 and 52. Due to lack of efficacy, the secukinumab 75 mg dose in <jats:styled-content style=\"fixed-case\">MEASURE<\/jats:styled-content> 2 was excluded from this pooled Asian subgroup analysis. Safety analysis included patients who received \u2265 1 dose of study treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 517 patients enrolled into the <jats:styled-content style=\"fixed-case\">MEASURE<\/jats:styled-content> studies, 69 (13.3%) were Asians: 46 in pooled secukinumab and 23 in placebo. At Week 16, <jats:styled-content style=\"fixed-case\">ASAS<\/jats:styled-content>20\/40 responses in Asian patients were 69.6%\/43.5% with pooled secukinumab versus 26.1%\/17.4% with placebo, which were comparable with rates reported in the overall study population. Secukinumab improved predefined efficacy endpoints at Week 16, with responses sustained through Week 52. Secukinumab was well tolerated in Asian patients, with a safety profile consistent with that reported in the overall study population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Secukinumab improved signs and symptoms, physical function, and disease\u2010specific QoL in Asian patients with active <jats:styled-content style=\"fixed-case\">AS<\/jats:styled-content>.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1756-185x.13094","type":"journal-article","created":{"date-parts":[[2017,5,25]],"date-time":"2017-05-25T17:15:50Z","timestamp":1495732550000},"page":"589-596","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Efficacy and safety of secukinumab in Asian patients with active ankylosing spondylitis: 52\u2010week pooled results from two phase 3 studies"],"prefix":"10.1111","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1235-0679","authenticated-orcid":false,"given":"James C.\u2010C.","family":"Wei","sequence":"first","affiliation":[{"name":"Division of Allergy, Immunology and Rheumatology Chung Shan Medical University Hospital Institute of Medicine Chung Shan Medical University Graduate Institute of Integrated Medicine China Medical University Taichung Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Baeten","sequence":"additional","affiliation":[{"name":"Academic Medical Centre Amsterdam The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joachim","family":"Sieper","sequence":"additional","affiliation":[{"name":"Charit\u00e9 University Medicine Berlin Berlin Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atul","family":"Deodhar","sequence":"additional","affiliation":[{"name":"Oregon Health &amp; Science University Portland Oregon USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vaishali","family":"Bhosekar","sequence":"additional","affiliation":[{"name":"Novartis Healthcare Pvt. Ltd. Hyderabad India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruvie","family":"Martin","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation East Hanover New Hampshire USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Porter","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation East Hanover New Hampshire USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,5,25]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60635-7"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket387"},{"key":"e_1_2_8_4_1","first-page":"17362","article-title":"Elevated serum levels of IL\u20106 and IL\u201017 may associate with the development of ankylosing spondylitis","volume":"8","author":"Liu W","year":"2015","journal-title":"Int J Clin Exp Med"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e32834640a9"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.151027"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22708"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000301"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2016.1167183"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39416"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2014.10.001"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12670"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2016.7"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202371"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314258"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)61134-5"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412679"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61134-4"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505066"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker270"},{"key":"e_1_2_8_21_1","first-page":"1753","article-title":"Changes of clinical response and bone biochemical markers in patients with ankylosing spondylitis taking etanercept","volume":"34","author":"Woo JH","year":"2007","journal-title":"J Rheumatol"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2008.23.5.852"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker087"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e3283621b8c"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.12188"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2007.01665.x"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2014.04.006"}],"container-title":["International Journal of Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1756-185X.13094","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1756-185X.13094","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T06:16:25Z","timestamp":1695536185000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1756-185X.13094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["10.1111\/1756-185X.13094"],"URL":"https:\/\/doi.org\/10.1111\/1756-185x.13094","archive":["Portico"],"relation":{},"ISSN":["1756-1841","1756-185X"],"issn-type":[{"value":"1756-1841","type":"print"},{"value":"1756-185X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"2017-05-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}